News Tag: Corporate Information

During the summer, a pilot project was carried out with twenty people from a group of several hundred interested who tested Dosell Consumer on their own behalf or to help a relative. Participants have continuously evaluated the product and given suggestions for improvements that iZafe Group is working to update ahead of the upcoming launch of Dosell Consumer.

After the test period, iZafe Group has made a final evaluation with the participants to identify how their medication has developed since they started using Dosell and to get information about their attitude to continue with the service.

"Dosell is my best friend – I never want to be without it." "The robot has reduced my medication misses on the weekends when you have a lot of other things scheduled." “I have received better continuous medication at fixed times. "Dosell increased the security of my mother and reduced my anxiety – Dosell can definitely extend the period of independence." "I would not be able to function without my Dosell." "My daughter does not want to be without Dosell and go back to manual handling of medication where I am constantly unsure and have to remind several times a day that medication should be taken." Dosell is missed by both the home care service and by my mother. It made it very easy to remember to take the medicine on time. It was calming to know that the medicine was delivered. " The words from users or relatives who participated as test persons in the pilot project during the summer of 2021 show that Dosell Consumer is an appreciated aid on the market that you do not want to be without.

“The interest in testing Dosell Consumer has been great and I can state that the response has been very good. The twenty people who participated in the test period have been completely different profiles, which indicates that Dosell is suitable for a number of different customer groups. As many as 95 percent want to keep their Dosell and continue with the service. They appreciate that Dosell is easy to use and that their compliance has improved. This strengthens us ahead of the upcoming launch to the public", says Anders Segerström, CEO of iZafe Group.

The enthusiastic response and the positive reception of the consumer version in Sweden means that iZafe Group is ready to start the launch in Italy via the Sempli Farma service, where the concept of sachets has been developed and spread more widely. The Italian market has a considerable potential with the equivalent of 8.8 million inhabitants over the age of 65 consuming more than five different medications per day. Of these, more than 50 percent experience difficulty following their medication treatments. In Italy, there is an accelerating need to automate medication management, where the consumer version of Dosell has been requested as the obvious alternative.

"The Italian market is several times as large as the Swedish and we see incredible potential for a broad rollout of Dosell now that Italy begins its digitalization journey in healthcare to give more people a safer and simpler medication at home, something that according to society's ambition contributes to lower healthcare costs with reduced risk of incorrect medication. The Italian sachets have been validated with Dosell and active marketing is done towards pharmacies.” concludes Anders Segerström.

Following the launch of Dosell Consumer in Sweden and Italy, iZafe Group sees great potential in a number of other markets in Europe, such as Norway, Finland, Spain, Portugal and England, where the company plans to find the right partners to launch the consumer version in longer term.

About Dosell Consumer
Dosell Consumer and the Dosell app are a niche version of iZafe Group's professional solution and adapted so that users and relatives can administer medication and ensure the right dosage themselves, without being dependent on healthcare professionals. Both versions of the product are compatible with sachets from all suppliers on the market.

Dosell Consumer is a subscription service. Subscriptions for Dosell Consumer can be subscribed for and paid for by, for example, relatives on behalf of the user.

Dosell Consumer will be available for delivery in October 2021, but it is already possible to register an interest for when Dosell Consumer is launched.

About Sempli Farma by Remedio
The Italian healthcare company Remedio has built a network of strategically selected partners in Italy to identify a combination of different aids to medication management and distribution channels that enable the elderly to remain at home longer. Unlike in Sweden, the possibility of receiving medicine separated into daily doses has not existed previously in Italy; this has inspired Remedio to launch the concept of sachets and develop a complete solution called Sempli Farma.

Sempli Farma is a service that, via pharmacies, connects doctors with the patient and their relatives through a closed drug-dispensing system. The aim of the care concept is to reduce care costs and streamline the Italian healthcare system. Dosell will become the ultimate end component by delivering the sachets while confirming that the medication has been taken and recording statistics.

Questions will be answered by Chief Executive Officer Anders Segerström and published at latest on September 14, 2021, on iZafe Group's investor site under the heading Financial Reports, Investor Questions.
 
Please send your questions to before 10:00 (10 a.m.) CET on Thursday, September 9, 2021.

Questions will be answered by Chief Executive Officer Anders Segerström and published on August 6, 2021 on iZafe Group's investor site under the heading Financial Reports, Investor Questions.

Please send your questions tobefore 10:00 (10 a.m.) CET on August 5, 2021.

As previously communicated, iZafe Group is launching a consumer version of the Dosell pharmaceutical robot to offer hundreds of thousands of patients and relatives a valuable and safe aid that can increase safety and compliance in medication regimes. At the end of June, a pilot project was launched with twenty people from a group of several hundred stakeholders who are now testing Dosell before launch, either on their own behalf or to help a relative.

“The interest in testing Dosell Consumer has been great. We have received good suggestions of small changes that can make a big difference in the user experience, however those who tested the robot highlight that it is simple and easy to understand, which is important because it should be able to be used even by those who have no prior knowledge of the system or of technology. This strengthens us for the upcoming launch to the public", comments Anders Segerström, CEO of iZafe Group.

During the test period, iZafe Group is conducting several evaluations and follow-ups using questionnaires to identify any areas of the service that need improving which will form the basis for the final product launched to the public.

"The instructions for getting started were very good, detailed and easy to understand." comments one of the participants in the consumer pilot project.

“We can only give positive feedback after my relative received her first sachet at the right time! Totally amazing." comments one of the relatives who is helping her daughter to test Dosell Consumer.

As previously announced, iZafe Group has signed a letter of intent with Apoteket AB to investigate the possibilities of signing a cooperation agreement between the parties and introduce Dosell in the consumer market in Sweden exclusively through Apoteket AB's channels. A collaboration with Apoteket would mean a faster and broader roll-out of Dosell in the consumer market in Sweden, jointly setting a new standard for handling medication, which means that digital, automatic drug dispensing using dose bags will become available to anyone who wants to create a safe and secure environment for administering drugs at home. As a first step, the launch of the consumer version will take place on the Swedish market followed by a launch on the Italian market via Sempli Farma.

“We want to inspire Italians to begin their digitalization journey in healthcare, so that more people receive safer and simpler medication at home, which contributes to lower healthcare costs with a reduced risk of incorrect medication. We have confirmed that the Italian sachets are compatible with Dosell, which is expected to be installed in Italian homes throughout 2021 and the year after.” Anders Segerström finishes.

In parallel with the launch of the consumer version in Sweden, iZafe Group is establishing a consumer version of Dosell in Italy as a significant component of the Sempli Farma care concept, where the concept of sachets has been developed and spread more widely. The Italian market has significant potential with the equivalent of 8.8 million people over the age of 65 consuming more than five drugs per day. In Italy, there is an accelerating need to automate drug management, and there Dosell will be the obvious choice.

About Dosell Consumer

• Dosell Consumer and the Dosell app are a niche version of iZafe Group's professional solution and adapted so that users and relatives can administer medication and ensure the right dosage themselves, without being dependent on healthcare professionals. Both versions of the product are compatible with sachets from all suppliers on the market.

• Dosell Consumer is a subscription service. Subscriptions for Dosell Consumer can be subscribed for and paid for by, for example, relatives on behalf of the user.

• Dosell Consumer will be available for delivery in September 2021, but it is already possible to register an interest for when Dosell Consumer is launched.

About Sempli Farma by Remedio
The Italian healthcare company Remedio has built a network of strategically selected partners in Italy to identify a combination of different aids to medication management and distribution channels that enable the elderly to remain at home longer. Unlike in Sweden, the possibility of receiving medicine separated into daily doses has not existed previously in Italy; this has inspired Remedio to launch the concept of sachets and develop a complete solution called Sempli Farma.

Sempli Farma is a service that, via pharmacies, connects doctors with the patient and their relatives through a closed drug-dispensing system. The aim of the care concept is to reduce care costs and streamline the Italian healthcare system. Dosell will become the ultimate end component by delivering the sachets while confirming that the medication has been taken and recording statistics.

Read iZafe Group's interview with Remedio's CEO Alessandro Iadecola here.

As previously communicated, iZafe Group is launching a consumer version of the Dosell pharmaceutical robot. As a result of limited advertising on social media, the company has received several hundred expressions of interest from private individuals who want to test Dosell on their own behalf or help a relative. In June, iZafe Group will start a pilot project with twenty selected people who have registered via a form on www.dosell.se to test Dosell for six weeks.

“The interest in testing Dosell Consumer has been great and we are pleased with the market's response. After the summer, our planned launch campaign will start with the goal of reaching a wide range of prospective customers and users of Dosell,” says Anders Segerström, CEO of iZafe Group AB. "Discussions are currently underway with potential partners that will mean a faster and broader roll-out of Dosell in the consumer market."

The goal of Dosell Consumer is to fundamentally change the care for users who want to live an independent life at home longer, but with the security that there are relatives and care staff who can intervene if something goes wrong. iZafe Group wants to set a new standard for digital dose dispensing in the home, which means that digital drug dispensing will be available to anyone who wants to create a safe and secure environment for dispensing medicines.

Dosell creates a safer life that allows users to live an independent life at home for a longer period of time, with a reduced risk of incorrect medication. This is valuable for, for example, elderly and multi-medicated people. Relatives who want to offer the service to their parents and other relatives also receive increased security with the support of the function for remote monitoring.

About Dosell Consumer

• Dosell Consumer and the Dosell app are a niche version of iZafe's professional solution and adapted so that users and relatives can administer and ensure the right medication themselves without being dependent on healthcare professionals.

• Dosell Consumer is a subscription service. Subscriptions for Dosell Consumer can be subscribed for and paid for by, for example, relatives on behalf of the user.

• Dosell Consumer will be available for delivery after the summer of 2021, but it is already possible to register an interest in securing availability when Dosell Consumer is launched.

With registration in the Medical Products Agency and certification under MDR, iZafe Group's pharmaceutical robot Dosell meets the requirements of the new regulation.

Dosell has been CE marked according to previously applicable directives for medical devices, MDD. The new EU Medical Device Regulation (MDR) replaced the MDD in May 2021. Like all medical device companies with products on the European market, iZafe Group has had to adapt its operations to meet the new requirements for CE marking of the products.

“Our pharmaceutical robot Dosell has been registered with the Medical Products Agency and certified under MDR. The MDR certification is important because it certifies that the product continues to meet the EU's essential health, safety, and environmental requirements. We have invested both time and financial resources to ensure that we comply with all new directives, and we are proud that we succeeded in submitting the application on May 26, when MDR replaced MDD.” says Anders Segerström, CEO of iZafe Group.

About the EU regulation
The regulation updates the rules on which medical devices may be on the market, and how products are provided and used. The regulation improves patient safety by introducing stricter methods for assessment and monitoring in the market. It also contains rules for how medical technology companies conduct product evaluations within the EU. This ensures that unsafe and incompatible products and equipment do not end up on the market.

For more information click here.

iZafe Group has together with partners developed an improved version of the pharmaceutical robot Dosell. Dosell 2.0 is the result of an ongoing work where iZafe Group, together with users, partners, and participants in pilot studies, exchanged experiences and documented data that provided important information for iZafe Group's ongoing development process. The gathered knowledge has formed a valuable base for future product and system development and by involving representatives from all stakeholder groups, we ensure that upgrades and improvements are customized. That is, iZafe Group shall prioritize functionality and product performance that is so close to the needs of users and customers that it guarantees that the product delivers value, safety, and health benefits.

“Our internal Customer Success group have been responsible for documenting the feedback we received from customers and partners with the aim of capturing early requests for the development of Dosell and the associated system. The feedback we regularly receive from ongoing pilot projects and from our partners, which is continuously born into our development processes, means that we make the right priorities and further improve Dosell with new functions to achieve enhanced performance. At the end of 2020, we received a total of 450 pre-orders of Dosell 2.0, which includes several improvements, including a new built-in and rechargeable battery with a battery life of over 48 hours and an improved app.” says Anders Segerström, CEO of iZafe Group.

iZafe Group attaches great importance to creating the best and most intuitive user experience in the market for pharmaceutical robots, and with the upcoming distribution of Dosell 2.0, the following features and operations have been further improved:

• We have replaced the alkaline batteries with built-in, rechargeable lithium-ion batteries that drastically extend the time that Dosell can operate without a power outlet connection.
• We launch a significantly improved alarm handling and a predefined alarm template.
• A safer and simpler process for loading a new sachet strip, which means shorter waiting time for the user.
• A simplified start-up process where Dosell more clearly indicates when the user can connect their smartphone to Dosell via Bluetooth.
• We have added a new, user-specific dosing window which means that the drug delivery becomes more flexible, giving the user increased freedom. Thus, there are more options for how doses should be dispensed, which can be controlled individually per Dosell to be adapted to the user's everyday life.

The past six months have been very development-intensive with investments in product, technology, and software. Major training efforts have been carried out with our partners who for two weeks have tested Dosell 2.0 with the help of a solid test schedule to evaluate all new functions, performance, and user experience. In addition, we have introduced new routines in the production process and updated our test and quality routines to ensure that Dosell 2.0 matches our high-quality standards.

“During the past six months, we have invested large resources, financially and with labor, to develop Dosell 2.0 based on our collaborations with partners and users. We are now in a final exciting phase which means that we are closing the window for further development of Dosell 2.0 and entering the production phase. It is estimated that the first units will be delivered to customers during week 20. Subsequent weeks, production will be scaled up to meet our customers' increased needs and to meet pre-orders that have already been made.” concludes Anders Segerström.
 

Questions will be answered by Chief Executive Officer Anders Segerström published on May 12, 2021 on iZafe's website under the heading Investor Relations.

Please send your questions tobefore 10:00 (10 a.m.) CET on May 3, 2021.